The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Looking for Brexit-proof portfolios? Try drugs, alcohol and tobacco

Wed, 29th Jun 2016 14:32

By Tricia Wright and Vikram Subhedar

LONDON, June 29 (Reuters) - Health, safety and even sometraditional 'sin stocks' have already shown signs of weatheringBrexit-related storms in European equity markets over the pastweek.

The flight to safety in the aftermath of last week's Brexitvote is sending investors scurrying back into healthcare andconsumer-related stocks that have shielded them from nearlyevery big market dislocation of the past five years.

On Wednesday, European healthcare became the first majorregional sector to recover all its post-Brexit losses, helpedlargely by the big UK bellwethers. Food and beverage stocks arepoised to follow.

Stocks such as AstraZeneca PLC, Diageo PLC and British American Tobacco PLC are up between 7percent and 11 percent since last Thursday's close.

They have led the broader market's recovery after more than$3 trillion was knocked off the value of global stocks in thetwo-day selloff that followed Britain's unexpected decision toleave the European Union.

The combination of dependable profits, dividends andexpectations that the weaker pound and euro will spur earningsupgrades for firms that sell mostly to consumers outside the UKand Europe has underpinned their resilience.

"There are three things at work but I think the first is thereach for dollar earnings," said Eric Moore, who runs the MitonIncome Fund from London.

"In a world where GDP is probably slowing everywhere,irrespective of Brexit, there's just more uncertainty," saidMoore, adding the relative stability of the so-called defensivesectors, whose profits are less reliant on economic growth,brightens their appeal.

The rally in bluechip healthcare and food and beveragestocks has even pushed the UK's FTSE 100 to less than apercent below its pre-Brexit level. In US dollar terms the indexis still more than 10 percent lower.

Outside of the UK, German real estate has found favour.Shares of Vonovia and Deutsche Wohnen areboth higher than where they were before last week's vote.

Both companies are focused on residential properties inGermany where low rates have contributed to steady price riseswhile low vacancy rates have put a floor under rents.

Gold mining stocks Rangold Resources and Fresnillo are up more than 20 percent as demand for the preciousmetal surged.

For a list of major European stocks that are above wherethey closed last Thursday see: http://reut.rs/295Lkwm

Goldman Sachs, which slashed its economic forecasts for theUK and Europe after the vote, now expects earnings in 2016 forthe Stoxx 600 to contract 5 percent.

Still, with German 10-year bund yields below zero the U.S.bank says equities offer value compared with other assets.

But given worries over the health of European banks andgrowth Goldman warns against broad-based buying and recommendsinvestors stick with food, beverage and tobacco and healthcareshares.

"The attractions of the more defensive or stable parts inequities are clear," said Goldman strategists in a note toclients.

(Reporting by Vikram Subhedar and Tricia Wright, additionalreporting by Tina Bellon in Frankfurt; Editing by Mike Dolan andToby Chopra)

More News
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more
26 Feb 2024 07:22

AstraZeneca's blood-disorder drug recommended for EU approval

(Sharecast News) - European regulators has given the green light to AstraZeneca's blood-disorder drug Voydeya, the biopharma giant announced on Monday.

Read more
22 Feb 2024 17:36

EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and Thursday and not separately reported by Alliance News:

Read more
20 Feb 2024 10:29

AstraZeneca acquires US-based biopharmaceutical company

(Sharecast News) - Drugmaker AstraZeneca revealed late on Monday afternoon that it had successfully completed its acquisition of US-based biopharmaceutical company Icosavax.

Read more
20 Feb 2024 09:40

LONDON BROKER RATINGS: JPMorgan cuts Airtel Africa price target by 28%

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
19 Feb 2024 16:51

LONDON MARKET CLOSE: Europe lacks direction on quiet Monday

(Alliance News) - European markets lacked direction on Monday, after a quiet day as the US markets celebrated George Washington's birthday.

Read more
19 Feb 2024 15:59

London close: Stocks manage gains on globally quiet day

(Sharecast News) - London's financial markets finished in positive territory on Monday, with stocks closing in the green after overcoming minor losses earlier in the session.

Read more
19 Feb 2024 15:39

UPDATE: AstraZeneca completes USD1.1 billion acquisition of Icosavax

(Alliance News) - AstraZeneca PLC on Monday said it has completed the acquisition of Icosavax Inc.

Read more
19 Feb 2024 11:51

LONDON MARKET MIDDAY: Stocks lack direction amid quiet start to week

(Alliance News) - Stock prices in London lacked direction at midday Monday, amid a quiet start to the week.

Read more
19 Feb 2024 08:44

LONDON MARKET OPEN: Stocks drift; Currys surges on takeover interest

(Alliance News) - Stock prices in London were looking for direction early Monday, as investors weighed possible trajectories for US interest rate cuts and a China's economic recovery.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.